Fascicle nerve grafts, methods for making same, and methods of treatment using same

JP2023547086A5Active Publication Date: 2024-11-05AXOGEN CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023524284
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-20
Filing Date
2021-10-21
Publication Date
2024-11-05
Estimated Expiration
2041-10-21

AI Technical Summary

Technical Problem

Current nerve grafts are limited in size and diameter, failing to meet the diverse needs of patients, and existing methods like autologous nerve grafting cause additional surgical complications and sensory loss.

Method used

Fascicular nerve grafts are prepared by removing the epineurial sheath and native extracellular matrix material using enzymes, allowing for nerve bundles to be aligned and entubated with biocompatible materials to create customized grafts of varying lengths and diameters.

Benefits of technology

This method enables the production of nerve grafts that better match patient needs, improving surgical efficiency and reducing complications by utilizing low-yield donors and enhancing axonal regeneration.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure provides fascicular nerve grafts of customizable length and diameter, and methods for preparing the same. The grafts are created by digesting the native extracellular matrix (ECM) and epineurial sheath surrounding nerve bundles of nerve tissue. One or more individual bundles can then be entubed into an entubation material, embedded in or coated with a coating material, or both, to form the fascicular nerve graft. The fascicular nerve graft is customizable and designed to bridge nerve gaps; its modularity allows it to restore continuity to nerve defects of virtually any length and to match the diameter of the recipient nerve in the patient.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present disclosure relates generally to the fields of neurobiology and medicine. More particularly, the present disclosure relates to fascicular nerve grafts, methods of making such nerve grafts, and methods of using such nerve grafts to treat nerve defects. [Background technology]

[0002] Nerve injury can cause various types of chronic pain, including neuropathic pain. Peripheral nerve injury is a common and rapidly increasing clinical problem caused by various accidental traumatic injuries. Peripheral nerve injury often leads to complete paralysis, paralysis, and loss of autonomic control of the corresponding body part. Surgical repair of nerve injury is currently the common treatment for such injuries, but outcomes are not ideal. Therefore, new strategies to improve axonal regeneration and target organ innervation after nerve injury are needed.

[0003] Neurons in the peripheral nervous system are understood to have a higher intrinsic regenerative potential than neurons in the central nervous system and can regenerate axons under appropriate environmental conditions. However, the peripheral nerve regeneration process is complex and controlled by multiple factors, including the microenvironment involved in nerve regeneration. Nevertheless, autologous nerve transplantation has been accepted as the gold standard for repairing peripheral nerve defects.

[0004] In many clinical situations, sufficient nerve tissue does not exist to allow tension-free reconstruction of peripheral nerves by direct end-to-end splicing of the transected nerve. In these cases, nerve grafts from different sources can be used to bridge the nerve gap. Nerve autografts typically require a second surgical site, which entails additional surgical time, permanent scarring, and sensory loss in the area of ​​the donor nerve, potentially resulting in persistent postoperative pain. An alternative to nerve autografts is the use of engineered nerve allografts or engineered nerve xenografts, both of which provide a biological substrate for nerve regeneration and, like nerve autografts, can be used without immunosuppression. Nevertheless, currently available commercial graft technologies are limited in that they may not be the correct "fit-match" for any particular surgical need. Summary of the Invention [Problem to be solved by the invention]

[0005] The quality and availability of nerve grafts, especially nerve grafts of length and diameter size appropriate for any particular patient's needs, remains a challenge. Indeed, currently available commercial nerve grafts are limited in size with respect to length and diameter, which may not meet the needs of all patients. [Means for solving the problem]

[0006] In accordance with the present disclosure, there is provided a fascicular nerve graft comprising one or more nerve bundles, the fascicular nerve graft being substantially free of epineurial sheath and native extracellular matrix material.

[0007] Additionally, the present disclosure provides a method of preparing a fasciculated nerve graft, the method comprising the steps of: providing at least one nerve tissue comprising one or more nerve bundles and comprising native extracellular matrix material and epineurial sheath; treating the at least one nerve tissue with an enzyme that degrades the native extracellular matrix material and epineurial sheath; washing the treated at least one nerve tissue to substantially remove and / or inactivate the enzyme and to substantially remove native extracellular matrix material degradation products and epineurial sheath degradation products, thereby producing one or more nerve bundles that are substantially free of native extracellular matrix material and epineurial sheath; and forming a fasciculated nerve graft from at least one nerve bundle of the one or more nerve bundles that is substantially free of native extracellular matrix material and epineurial sheath.

[0008] Those skilled in the art will understand that the nerve grafts, methods of preparing nerve grafts, and methods of treatment using nerve grafts disclosed herein may be used in surgical interventions in humans and other vertebrates, as well as in laboratory studies, comparisons, and assays.

[0009] Those skilled in the art will also understand that starting materials, biological materials, biocompatible materials, components, growth factors, pharmaceuticals, enzymes, and solutions, therapies, drugs, and methods of preparation and treatment, other than those specifically exemplified, can be utilized in the practice of this disclosure without resort to undue experimentation. All art-known functional equivalents of any such materials and methods are intended to be included in this disclosure.

[0010] The methodologies described herein for preparing and delivering procedures using fascicled nerve grafts may better enable the use of low-yield donors whose nerves might otherwise be rejected based on their diameter or insufficient number of fascicles. For example, the present disclosure provides for combining fascicles isolated from more than one harvested nerve to create a fascicled nerve graft of a desired length and diameter. Thus, the disclosed methods may, for example, improve the yield of usable donor nerves and make the transplant process more efficient and economical.

[0011] Other objects, features, and advantages of the present disclosure will become apparent from the following detailed description. However, it should be understood that the detailed description and examples, while indicating illustrative embodiments of the present disclosure, are given for illustrative purposes only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. It should be noted that just because a particular compound is ascribed to one general formula does not mean that it cannot also belong to another general formula.

[0012] The singular forms "a," "an," and "the" include plural referents unless the context dictates otherwise. The terms "approximately" and "about" indicate being approximately the same as a reference number or value. As used herein, the terms "approximately" and "about" should generally be understood to encompass ±5% of the specified amount or value. The use of the term "or" in the claims is used to mean "and / or," unless expressly indicated to represent alternatives only, or unless the alternatives are mutually exclusive, even if the disclosure supports the definition of representing alternatives only and "and / or." As used herein, "another" can mean at least a second or more. Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error for the device, method utilized to determine the value, or the variation that exists among study subjects.

[0013] Both the foregoing general description and the following detailed description are exemplary and explanatory only and are not limiting of the features as claimed. As used herein, the terms "comprises," "comprising," "including," "having," or other variations thereof are intended to cover a non-exclusive inclusion, and thus a process, method, article, or apparatus comprising a list of elements may include not only those elements, but also other elements not expressly listed or inherent in such process, method, article, or apparatus. Additionally, the term "exemplary" is used herein to mean "example" rather than "ideal." Additionally, the term "between," when used in describing a range of values, is intended to include the minimum and maximum values ​​set forth herein.

[0014] The terms and expressions employed are used as terms of description and not as terms of limitation, and there is no intention in the use of such terms and expressions to exclude any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the present disclosure as claimed.

[0015] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. The present disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of illustrative embodiments presented herein. [Brief explanation of the drawings]

[0016] [Figure 1] Cross section of peripheral nerve tissue. [Figure 2] Diagram of nerve bundles of peripheral nerve tissue shown in Figure 1 after removal of epineurial sheaths and native extracellular matrix material, and isolation of individual nerve bundles. [Figure 3] Diagram of an individual nerve bundle, such as the one shown in Figure 2, placed on a sheet of biomaterial. [Figure 4]4 is a diagram of the nerve bundle shown in FIG. 3 and a nerve graft formed from a sheet of biomaterial. [Figure 5] Illustrated stained nerve tissue reflecting nerve bundles and extracellular matrix material prior to treatment of the nerve tissue with enzymes. [Figure 6] Diagram of stained nerve bundles after the nerve tissue has been treated with enzymes. DETAILED DESCRIPTION OF THE INVENTION

[0017] The nerve grafts of the present disclosure can be prepared in a wide variety of lengths and diameters to match various operational needs. Thus, the present disclosure can provide more successful nerve regeneration and better patient outcomes. Illustrative nerve grafts, associated methods for their preparation, and associated methods of treatment using the nerve grafts are described in detail below.

[0018] According to some embodiments of the present disclosure, preparing a nerve graft includes providing nerve tissue having one or more nerve bundles. 1-4 illustrate an example of nerve tissue 100 used to prepare a fascicular nerve graft 114. The specific features depicted in FIGS. 1-4 are merely illustrative and do not limit the scope of the present disclosure. FIG. 1 shows a cross-sectional view of nerve tissue 100 including a nerve bundle 102, native extracellular matrix (ECM) material 104, and an epineurial sheath 106. The nerve tissue 100 may include one nerve bundle, or may include more than one nerve bundle 102 as shown in FIG. 1. Nerve tissue 100 suitable for use in the present disclosure may be obtained from an animal, such as a mammal, e.g., a human or non-human mammal. More than one nerve tissue 100 may be used in the methods described herein, and nerve bundles 102 from more than one type of nerve tissue 100, e.g., human and non-human nerve tissue, or non-human nerve tissue from different non-human mammals, may be combined in the preparation of a fascicular nerve graft 114. The fascicular nerve graft 114 shown in Figure 4 may be prepared from nerve tissue 100 isolated from a human, non-human animal, or other vertebrate. The starting nerve material may be obtained from any suitable nerve tissue within the body. The starting nerve material may include peripheral nerve tissue or spinal nerve tissue and may ultimately be used to form a nerve graft for peripheral or spinal nerve transplantation.

[0019] A fascicular nerve graft according to the present disclosure (including the illustrated fascicular nerve graft 114) may be allogeneic or xenogeneic to the patient treated with the fascicular nerve graft. In the example of Figures 1-4, the fascicular nerve graft 114 may comprise a three-dimensional microstructural scaffold of nerve tissue 100 and include protein components native thereto. Also contemplated herein are methods including one or more immunosuppressive techniques performed on nerve tissue (such as nerve tissue 100) and / or a fascicular nerve graft prepared from nerve tissue (e.g., fascicular nerve graft 114 prepared from nerve tissue 100) before and / or after implantation in a patient. For example, donated nerve tissue may be processed to selectively remove cellular components and / or debris prior to incorporation of the fascicle into the fascicular nerve graft, and / or the nerve tissue may be processed to selectively remove cellular components and / or debris prior to treatment with the methods described herein.

[0020] Preparation of an illustrative fascicular nerve graft 114 according to the methods herein may include treating the nerve tissue 100 with one or more enzymes that at least partially or completely degrade the native ECM material 104 and epineurial sheath 106. The enzymes may include, for example, collagenase type IV, other types of collagenase (I or III, up to a concentration of 1 mg / mL), or matrix metallopeptidase (MMP) (e.g., MMP7 or MMP12) at a concentration of up to 1:20 in an aqueous-based solution such as phosphate-buffered saline (PBS) or saline.

[0021] The step of treating the nervous tissue (e.g., nervous tissue 100) with an enzyme may be performed at a temperature between about 4°C and about 37°C, such as between about 4°C and about 15°C, between about 10°C and about 20°C, or between about 20°C and about 30°C. Additionally, the step of treating the nervous tissue 100 with an enzyme may be performed for a period of about 2 hours to about 24 hours, such as between about 2 hours to about 5 hours, between about 8 hours to about 12 hours, between about 16 hours to about 24 hours, or between about 6 hours to about 12 hours. In at least one example, the step of treating the nervous tissue 100 with an enzyme may be performed at a temperature between about 35°C and about 40°C for a period of about 2 hours to about 6 hours, particularly at a temperature of about 37°C for a period of about 2 hours to about 4 hours. In at least one example, the step of treating the nervous tissue 100 with an enzyme may be performed at a temperature between about 4°C and about 6°C for a period of about 4 hours to about 24 hours. The step of treating the nerve tissue 100 with the enzyme may be carried out with agitation.

[0022] The processed nerve tissue, including individual nerve bundles (e.g., nerve bundles 102), can then be washed to remove any remaining enzymes and / or debris remaining from the processed nerve tissue. That is, the method may include washing the processed nerve tissue to remove enzymes, residual native ECM material, or epineurial sheath degradation products. In some embodiments, washing the processed nerve tissue may inactivate enzymes by balancing the pH. Performing the washing step may completely or at least partially remove and / or inactivate enzymes. Washing the processed nerve tissue may be performed using a solution such as, for example, phosphate-buffered saline (PBS), serine-containing serum, or a combination thereof. Washing the processed nerve tissue may be performed with agitation. Additionally, washing the processed nerve tissue may be performed at a temperature between about 4°C and about 40°C. Furthermore, washing the processed nerve tissue may be performed for a period between about 1 minute and about 4 hours. Furthermore, the step of washing the processed nerve tissue may be performed more than once, for example, two, three, or four or more times. The processed nerve tissue may be washed sufficiently to remove native ECM material and epineurial sheath, thereby producing one or more nerve bundles that are free of native ECM material and epineurial sheath or that are substantially free of native ECM material and epineurial sheath. As used herein, the phrase "substantially free of native ECM material" means that all or at least 50% of the native ECM material has been removed. In certain embodiments, one or more nerve bundles that are substantially free of native ECM material have at least about 85% or at least about 95% of the native ECM material removed. In other embodiments, one or more nerve bundles that are substantially free of native ECM material have at least about 99% or all of the native ECM material removed. Additionally, one or more of the nerve bundles that are substantially free of epineurial sheaths have at least about 95%, at least about 99%, or all of the epineurial sheaths removed.

[0023] Additionally or alternatively, the method may include suspending and incubating the treated and washed neural tissue in a solution. Incubation may be performed at a temperature of about 4°C to about 37°C, such as about 4°C to about 15°C, about 10°C to about 20°C, or about 20°C to about 30°C. Incubation may be performed for a period of about 45 minutes to about 24 hours, such as about 1 hour to about 2 hours, about 3 hours to about 8 hours, about 6 hours to about 12 hours, or about 12 hours to about 24 hours. For example, incubation may be performed at a temperature of about 4°C for a period of about 6 hours to about 24 hours. In another example, incubation may be performed at a temperature of about 37°C for a period of about 45 minutes to 60 minutes. In some embodiments, incubation may be performed at 37°C for a period of about 3 hours to about 5 hours, e.g., about 4 hours at 37°C. Although exemplary ranges of duration and temperature are listed herein, generally, the duration of incubation can be increased as the incubation temperature decreases. The steps of suspending the neural tissue, incubating the neural tissue, or both may be performed with stirring. The solution used for suspension and incubation may contain a serine component including at least alpha-antitrypsin and alpha-2-macroglobulin. The solution may be a serine-containing serum. For example, the solution may contain fetal bovine serum, goat serum, horse serum, pig serum, sheep serum, chicken serum, or rabbit serum.

[0024] Additionally or alternatively, the method may include washing the suspended and incubated neural tissue with a buffered solution to remove the solution used in the step of suspending the washed neural tissue. The buffered solution may have a pH between about 6.8 and about 7.8, e.g., about 7.2, about 7.4, or about 7.6. In at least one example, the suspended neural tissue may be washed with the buffered solution at a temperature of about 37°C for a period of about 45 minutes to about 55 minutes. In at least one example, the suspended neural tissue may be washed with the buffered solution at a temperature of about 4°C for a period of about 1 hour to about 6 hours. Additionally, the step of washing the suspended neural tissue with the buffered solution may be performed with agitation. The buffered solution may include, for example, phosphate-buffered saline or other suitable buffers.

[0025] The nerve bundles of the processed and washed nerve tissue can then be separated from one another, thereby producing isolated nerve bundles. Figure 2 shows five isolated nerve bundles 108 derived from the nerve tissue 100 (i.e., the five isolated nerve bundles 108 in Figure 2 corresponding to five of the six nerve bundles 102 shown in Figure 1). Any number of isolated nerve bundles can then be substantially aligned (optionally combined with one or more nerve bundles from one or more other samples of nerve tissue—including when those samples of nerve tissue are derived from different sources) and entubated on the non-end side by wrapping or rolling to prepare a fasciculated nerve graft (e.g., fasciculated nerve graft 114) comprising one or more nerve bundles free of, or substantially free of, native ECM material and / or epineurial sheath. Figure 3 shows seven isolated nerve bundles 108, including the five isolated nerve bundles 108 derived from the nerve tissue 100 shown in Figure 3 and two additional isolated nerve bundles 108 derived from different nerve tissue. 3 and 4, a fascicular nerve graft 114 may be formed from an entubation material 110 that includes at least one isolated nerve bundle (e.g., multiple isolated nerve bundles 108) and a biocompatible material surrounding the nerve bundles 108. All of the nerve bundles 108 used to form the fascicular nerve graft 114 may be from the same nerve tissue, or one or more of the nerve bundles 108 may be combined with one or more other bundles obtained from other nerve tissue. Such other nerve bundles may be obtained from nerve tissue that has been processed and washed in the same manner as described above.

[0026] The individual bundles used to prepare a fasciculated nerve graft (e.g., fasciculated nerve graft 114) according to the present disclosure are not substantially altered or damaged by the processing methods used in processing nerve tissue (e.g., nerve tissue 100) and subsequent washing and incubation. The enzyme substantially digests the native ECM material of the nerve tissue (e.g., native ECM material 104 of nerve tissue 100) and the epineurial sheath (e.g., epineurial sheath 106) without substantially damaging the nerve bundles. Suitable enzymes for digesting the native ECM material and epineurial sheath without altering or damaging the nerve bundles include those described above, e.g., specific and nonspecific collagenases or collagen-specific enzymes or chemicals. For example, collagenase type IV may be used to remove the native ECM material and epineurial sheath. An enzyme that does not alter or damage nerve bundles is an enzyme that leaves the bundles and the perineurium surrounding each bundle substantially intact and of sufficient quality for handling the nerve bundles. Additionally, the perineurium surrounding each bundle may be affected during processing of the nerve tissue while the nerve bundle remains substantially intact and of sufficient quality for handling. As used herein, the term "substantially intact and of sufficient quality for handling" means one or more of the following: the nerve bundle has the ability to be manipulated, e.g., picked up using a tool such as tweezers, without disruption; the nerve bundle may maintain a similar morphology and shape to that of the nerve bundle in native nerve tissue (e.g., nerve bundle 102 in nerve tissue 100); the nerve bundle remains in a solid, non-flowing state; or the physical properties of the nerve bundle, such as tensile strength and elastic modulus, may be similar to those of the nerve bundle in native nerve tissue (e.g., nerve bundle 102 in nerve tissue 100). Figure 5 shows a laminin-stained nerve bundle 102 surrounded by native ECM material 104 prior to treatment with one or more enzymes according to the methods herein. 6 shows the same laminin-stained nerve bundle 102 after processing, where the native ECM material 104 and epineurial sheath 106 have been removed while leaving the nerve bundle 102 intact. Example 1 below describes a method of processing and cleaning nerve tissue, such as nerve tissue 100, according to the present disclosure.

[0027] According to some embodiments, the processed and separated nerve bundles are aligned (if more than one bundle is used) and entubated, including by wrapping them in a biocompatible entubation material. The entubation material may be any material of sufficient strength to be manipulated, e.g., picked up with a tool such as tweezers, while maintaining its shape, and may be, for example, a sheet, sheath, tube, gel, or adhesive. The entubation material may be any material capable of holding the bundles together in a shape representative of the shape of a native nerve (e.g., nerve tissue 100). Additionally, the entubation material may be formed of any material or combination of materials of sufficient strength to withstand the insertion of a suture therethrough for attachment of the entubation material to nerve endings or another material. FIG. 3 illustrates an exemplary entubation material 110 in the form of a sheet, as shown in FIG. 3. Alternatively, a nerve bundle (e.g., nerve bundle 108) may be entubated by surrounding the non-terminal sides of the bundle with a tube comprising a biocompatible material. Entubation materials may include various materials or combinations of materials, which may be natural or synthetic. Illustrative biocompatible materials suitable for use as entubation materials to form the bundled nerve grafts herein include, but are not limited to, intact ECM, collagen (including, but not limited to, isolated type-I collagen or additional types of collagen, including types II, III, IV, V, and IV), synthetic biodegradable materials (such as polyesters, such as polylactide (PLA), polylactic-co-glycolic acid (PLGA), poly-L-lactic acid (PLLA), polyethylene glycol (PEG), or polycaprolactone (PCL)), polysaccharides (including, for example, chitosan, alginate, cellulose), polydioxanone (PDS), polymers (including, for example, protein-based polymers), fibrinogen, fibrin, gelatin, and hydrogels. Biocompatible materials used as entubation materials may be biodegradable. Further details of suitable biocompatible materials are listed below.The sheet of entubation material may be positioned to surround and contain one or more individual nerve bundles of any desired configuration and size, including configurations and sizes customized for the patient's needs. In some instances, a biocompatible adhesive or sealant may be used to prepare the bundled nerve graft. For example, if the entubation material includes one or more seams requiring closure (e.g., a sheet rolled into a tube), the seams may be closed (e.g., the edges of the sheet may be joined and sealed together) through the use of a biocompatible adhesive or sealant. Examples of adhesives or sealants that may be used to close seams according to the present disclosure include, but are not limited to, biologically derived or synthetic materials, including PEG, fibrin glue, isolated type-I collagen (or additional types of collagen, including types II, III, IV, V, and IV), and light-curing adhesives. The sealant or adhesive may ensure similar mechanical properties and elastic modulus to peripheral nerve tissue.

[0028] Alternatively, or in addition, the step of entubing at least one nerve bundle (e.g., nerve bundle 108) to prepare a fasciculated nerve graft (e.g., fasciculated nerve graft 114) may include embedding or coating the nerve bundle in a coating material that is a biocompatible material or a combination of biocompatible materials. The coating material may, for example, be in gel form or may include an adhesive, or both a gel and an adhesive. The biocompatible material used as the coating material may be the same as or different from the biocompatible materials described above for use as the entubation material, in cases where the nerve bundle is both encased in the entubation material and embedded or coated with the coating material. For example, after aligning the nerve bundles on the entubation material, the aligned nerve bundles may be embedded in a coating material and then encased in the entubation material. Alternatively, for example, the nerve bundles may be aligned on the entubation material and embedded or coated with a coating material before being encased in the entubation material. As another alternative to the coating process, the nerve bundle may be aligned on the entubation material and a thick layer of coating material may be applied to the entubation material (i.e., the coating material (e.g., coating material 112 shown in Figures 3 and 4) is spread onto the entubation material) before the nerve bundle is encased in the entubation material.

[0029] Alternatively or additionally, embedding or coating nerve bundles to prepare a fasciculated nerve graft may include at least partially or completely filling the spaces between the nerve bundles with a filler material comprising a biocompatible material or combination of biocompatible materials, including one or more of gel, collagen, gelatin, polysaccharide, hydrogel, fibrin, fibrinogen, alginate, cellulose, chitosan, or extracellular matrix material. The biocompatible material used as the filler material may be the same as or different from the biocompatible material used as the entubation material, and in cases where the filling step is performed in addition to coating the nerve bundles, it may be the same as or different from the biocompatible material used as the coating material. For example, a layer of filler material may fill the space between the nerve bundles and the entubation material and / or the space between the nerve bundles. That is, a method of preparing a bundled nerve graft may include, for example, aligning nerve bundles on an entubation material, encasing the aligned nerve bundles in the entubation material, and then adding, for example, by injection, a filler material to the spaces within the entubation material between the entubed nerve bundles.

[0030] The methods herein can be used to produce nerve grafts of desired dimensions, having a desired length, circumference, and cross-sectional dimension (width, such as diameter, in the case of a cylindrical nerve graft). To that end, the number of individual nerve bundles used to prepare the fasciculated nerve graft can include any number of nerve bundles appropriate to achieve a nerve graft of the desired width (or diameter), e.g., two or more bundles. That is, in some embodiments, the fasciculated nerve graft includes a single nerve bundle, and in other embodiments, the fasciculated nerve graft includes more than one nerve bundle 108. For example, the fasciculated nerve graft can include multiple bundles, such as at least two, at least three, at least four, at least five, at least eight, at least ten, at least twelve, or at least sixteen nerve bundles. In some instances, the nerve graft comprises 2-20 nerve bundles, 5-15 nerve bundles, 14-18 nerve bundles, or even more than 20 nerve bundles, depending on the size of the nerve bundle, the location in the patient's body where the fascicular nerve graft will be used, and the nature of the nerve to which the fascicular nerve graft will be attached.

[0031] A fascicular nerve graft (e.g., fascicular nerve graft 114) may have dimensions appropriate to the surgical needs of a patient, and the number of nerve bundles used to form the fascicular nerve graft may be determined, at least in part, based on the dimensions of the nerve bundle or bundles and the desired dimensions of the fascicular nerve graft, including as determined by the specifics of its location and surgical site within the patient. According to some aspects of the present disclosure, a fascicular nerve graft may include nerve bundles that are substantially similar in diameter to one another; alternatively, a fascicular nerve graft may comprise two or more individual nerve bundles of substantially dissimilar diameters to one another; and further, a fascicular nerve graft may comprise individual nerve bundles, some of which have substantially similar diameters to one another and others of which have substantially dissimilar diameters to one another. The diameter of each nerve bundle (e.g., each nerve bundle 108) can be between about 50 μm and about 1 mm, between about 50 μm and about 5 mm, e.g., between about 100 μm and about 500 μm, between about 250 μm and about 750 μm, between about 600 μm and about 900 μm, between about 750 μm and about 1 mm, or between about 750 μm and about 5 mm.

[0032] The size of the fascicle nerve graft is selected to match the fascicle portion and / or overall diameter of the recipient nerve. Thus, the number and size of the bundles used to form the nerve graft can be selected to match the overall size of the fascicle nerve graft to the number and / or size of the recipient nerve bundles. The fascicle nerve graft (e.g., fascicle nerve graft 114) may have a diameter between about 50 μm and about 10 mm, e.g., between about 100 μm and about 500 μm, between about 250 μm and about 750 μm, between about 600 μm and about 900 μm, or between about 750 μm and about 5 mm. Individual bundles may have a minimum diameter of about 10 μm. For any single desired diameter of the fascicle nerve graft, it may be possible to prepare the fascicle nerve graft from one bundle or more than one bundle. In cases where the fascicle nerve graft is formed from more than one nerve bundle, the nerve bundles used to form the fascicle nerve graft may be substantially similar in diameter. As used herein, "substantially similar in diameter" means that the nerve bundles have diameters within ±20% of each other. Alternatively, the nerve bundles used to form the fascicled nerve graft may be different from each other. And, as noted above, the number of bundles used may depend on the size of the nerve bundle, as well as the location in the patient's body where the fascicled nerve graft will be used and the nature of the nerve to which the fascicled nerve graft will be attached.

[0033] Methods of forming a fascicular nerve graft (e.g., fascicular nerve graft 114) herein may include modifying the length of multiple nerve bundles (e.g., nerve bundle 108), e.g., to provide multiple nerve bundles of substantially the same length as one another. For example, nerve bundles may be trimmed or cut by any suitable technique before, during, or after combining the nerve bundles into a fascicular nerve graft prepared by any of the above methods, which may include one or more of the following steps: entubating, embedding or coating, and / or filling, as described above. In some embodiments, to best prevent axonal escape or neuroma formation, each nerve bundle should be continuous from one end of the nerve graft to the other. Fascicular nerve grafts may be formed to have lengths of between about 3 mm and about 200 mm, such as between about 5 mm and about 100 mm, between about 20 mm and about 50 mm, between about 45 mm and about 75 mm, or between about 15 mm and about 40 mm. Furthermore, for example, fascicular nerve grafts can be approximately 100 mm 3 ~approx. 25,000mm 3 , approximately 500 mm 3 ~approx. 10,000mm 3 , approximately 1,000 mm 3 ~approx. 5,000mm 3 , approximately 500 mm 3 ~approx. 2,000mm 3 , approximately 100 mm 3 ~about 5000mm 3 , or approximately 7,500 mm 3 ~approx. 15,000mm 3 etc., about 5 mm 3 ~approx. 55,000mm 3 A total volume in the range of

[0034] The fascicular nerve grafts described herein (e.g., fascicular nerve graft 114) may include one or more of nerve growth factors, cells, a mix of cells including multiple cell types in a mixed cell population, a cellular component, a nonsteroidal anti-inflammatory drug, or an immunosuppressant, any of which may be included at any time during the formation of the fascicular nerve graft and / or added to the fascicular nerve graft after its formation. Additionally, the immunosuppressive techniques and immunophilic agents described in U.S. Provisional Patent Application No. 63 / 071,635, the entire contents of which are incorporated herein by reference, may be used for regenerative and immunosuppressive activity in the fascicular nerve grafts of the present disclosure.

[0035] A fascicle nerve graft (e.g., fascicle nerve graft 114) prepared according to the methods described herein may be used in methods of treating a patient, for example, to reconstruct a peripheral nerve discontinuity to support axonal regeneration across a nerve gap. The patient may be a human or a non-human animal (e.g., a cat, dog, horse, etc.). For example, a fascicle nerve graft used in treatment according to the methods herein may be implanted through a surgical procedure. In an exemplary procedure, a surgeon or other medical professional may examine the patient's tissue at the site of interest and, if necessary, resect scar tissue. Proximal and distal segments of the damaged nerve may be dissected down to healthy tissue, for example, by visual and tactile signs. Furthermore, the surgeon may measure the distance between the nerve endings defining the nerve gap and the diameter of the damaged nerve to select a fascicle nerve graft of the appropriate length and diameter. A fascicle nerve graft prepared according to the present disclosure may then be implanted in the patient. The surgeon may use sutures to connect the fascicle nerve graft to the nerve endings defining the nerve gap. Optionally, treating the patient may include analgesic therapy and / or administration of nonsteroidal anti-inflammatory drugs, growth factors, or immunosuppressants. Such drugs may be introduced into the fascicular nerve graft and / or administered separately to the patient, as described above. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, can alleviate pain, reduce fever, prevent blood clots, and, at relatively higher doses, reduce inflammation. Such NSAIDs may be nonselective in inhibiting the activity of both cyclooxygenase enzymes (COX-1 and COX-2), or may be COX-2 selective and be used to inhibit COX-2 activity. Immunosuppressants may help prevent unwanted immune responses to the implanted fascicular nerve graft. Immunosuppressants useful in the present disclosure may include, but are not limited to, steroids (including, but not limited to, testosterone and estrogens), glucocorticoids, cytostatic drugs, antibodies, drugs that act on immunophilins, and other immunosuppressants.Immunophilin ligands such as FK506 improve nerve regeneration through independent mechanisms of action while providing immunosuppressive properties.

[0036] As noted above, the fascicled nerve grafts described herein (e.g., fascicled nerve graft 114) may be formed by combining one or more nerve bundles (e.g., nerve bundle 108) with one or more biocompatible materials, as well as other optional supplemental materials. In particular, to form the fascicled nerve graft, the nerve bundles may be entubed (e.g., wrapped or surrounded) in an entubation material (e.g., entubation material 110 shown in FIGS. 3 and 4), embedded in or coated with a coating material (e.g., coating material 112 shown in FIGS. 3 and 4), and / or surrounded by a filler material, where the entubation material, coating material, and / or filler material comprise one or more biocompatible materials, including biocompatible materials that are biodegradable. The biocompatible materials listed below may be used to fill the spaces between the bundles. Biocompatible materials may be used to embed the bundles within the final construct (i.e., the final fascicular nerve graft). In some embodiments, biocompatible materials may be used to coat the outer layer of the final product. As described in more detail below, various materials, including one or more of non-native ECM materials, collagen, chitosan, alginate, biodegradable polymers, cellulose, fibrinogen, fibrin, protein-based polymers, gelatin, polysaccharides (other than chitosan, alginate, or cellulose), optionally in the form of a hydrogel, may be used to entubate and / or embed or coat one or more nerve bundles and / or fill the space around one or more nerve bundles. The listed ECM materials and proteins are considered general biocompatible proteins that allow for stabilization of nerve bundles within the fascicular nerve graft and help prevent soft tissue infiltration within the implanted tissue.

[0037] As noted above, the entubation and / or coating materials may include non-native ECM materials, i.e., ECM materials added after a portion of the native ECM material and the epineurial sheath have been removed. The non-native ECM materials may be obtained from different types of tissue or different species. In addition, non-native ECM materials include, but are not limited to, laminins (e.g., laminin alpha-2, laminin alpha-4, laminin alpha-5, laminin beta-1, laminin beta-2, laminin gamma-1), collagens (e.g., collagen IV alpha-1(IV) chain, collagen IV alpha-1 / 5(IV) chain, collagen alpha IV-2 chain, collagen alpha IV-3 chain, collagen I alpha-1 chain, collagen alpha-2(I) chain, collagen alpha-3(VI) chain, collagen alpha), collagen alpha-1 chain, collagen alpha-2(I) chain, collagen alpha-3(VI) chain, ... The proteins may include collagen alpha-1(VI) chain, collagen alpha-1(XXVIII) chain, collagen alpha-1(III) chain, collagen alpha-3(V) chain, collagen alpha-1(XVI) chain, collagen alpha-1(XXI) chain, collagen alpha-2(VI) chain, collagen alpha-1(VIII) chain, collagen alpha-1(V) chain, collagen alpha-1(II) chain, collagen alpha-1(XIV) chain, collagen alpha-1(XII) chain), fibronectin (e.g., fibronectin 1 (type-III 4, 7 domains)), asporin, perlecan, nidogens (e.g., nidogen-1, nidogen-2), lumican, dermatopontin, keratin, type II cytoskeleton 1, fibrillin-1, decorin, vitronectin, myelin protein P0, myelin P2 protein, asporin, prolargin, biglycan, periostin, and alpha-crystallin B chain.Of these, at least the following proteins are believed to contribute to the regenerative capacity of nerve grafts: laminin alpha-2, laminin alpha-4, laminin alpha-5, laminin beta-1, laminin beta-2, laminin gamma-1, collagen IV alpha-1(IV) chain, collagen IV alpha-1 / 5(IV) chain, collagen alpha IV-2 chain, collagen alpha IV-3 chain, fibronectin 1 (type-III 4,7 domain), perlecan, nidogen-1, and nidogen-2. The non-native ECM material may comprise one or more of the types of native ECM material that were present in the nerve tissue from which the nerve bundle or bundles are obtained prior to its processing.

[0038] The biocompatible entubation and / or coating material may additionally or alternatively comprise one or more types of collagen. The collagen may be in the form of a scaffold formed, for example, from a thin sheet. While other types of collagen, such as collagen II, III, IV, and / or V, may also be included in the composition, collagen I is particularly contemplated. Other types of collagen may be included, including those grouped as fibrillar (types I, II, III, V, XI), non-fibrillar, FACIT (fibrillar-associated collagen with interrupted triple helices) (types IX, XII, XIV, XIX, XXI), short chain (types VIII, X), basement membrane (type IV), multiplexin (multiple triple helical domains with interruptions) (types XV, XVIII), MACIT (membrane-associated collagen with interrupted triple helices) (types XIII, XVII), or other (types VI, VII) collagens. Generally, collagen I and collagen III may be preferred when these types comprise native ECM materials. These collagens may be derived, for example, from bovine, equine, porcine, or human sources, and may be used in combination with silicones, glycosaminoglycans, fibroblasts, and / or growth factors.

[0039] A fascicular nerve graft (e.g., fascicular nerve graft 114) may additionally or alternatively include one or more polysaccharides as a biocompatible material. Any type of biocompatible, biodegradable polysaccharide may be used. Such polysaccharides may include, but are not limited to, chitosan, alginate, or cellulose. The cellulose may include any one or more types of cellulose I, II, III, or IV.

[0040] The fascicular nerve graft (e.g., fascicular nerve graft 114) may include one or more biocompatible polymers, such as one or more biodegradable polymers. Additionally or alternatively, the fascicular nerve graft (e.g., fascicular nerve graft 114) may include one or more protein-based polymers. In some examples, the fascicular nerve graft (e.g., fascicular nerve graft 114) may include polyethylene glycol (PEG), also known as polyethylene oxide (PEO) or polyoxyethylene (POE), depending on its molecular weight.

[0041] A fascicular nerve graft (e.g., fascicular nerve graft 114) may additionally or alternatively include fibrin (also called factor Ia) and / or fibrinogen, which may facilitate stabilization of the fascicle and fascicular nerve graft generally.

[0042] A fascicular nerve graft (e.g., fascicular nerve graft 114) may additionally or alternatively include gelatin, which is derived from collagen. Gelatin may also be referred to as hydrolyzed collagen, collagen hydrolysate, gelatin hydrolysate, and / or hydrolyzed gelatin. Gelatin may facilitate stabilization of fascicles and fascicular nerve grafts in general.

[0043] The fascicular nerve graft (e.g., fascicular nerve graft 114) may comprise a hydrogel. The hydrogel may be composed of any one or combination of, but not limited to, cellulose, any derivative of cellulose, or hyaluronic acid. The hydrogel may be crosslinked to adjust its mechanical properties. The hydrogel may have a natural or synthetic origin.

[0044] The fascicular nerve graft (e.g., fascicular nerve graft 114) may additionally or alternatively contain nerve growth factor (NGF), sometimes described as 7S (a 130 kDa complex of three proteins—α-NGF, β-NGF, and γ-NGF (in a 2:1:2 ratio) (proNGF (NGF precursor))), or may be one of the following types: brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4, also known as NT4, NT5, NTF4, and NT-4 / 5), the endogenous steroid dehydroepiandrosterone (DHEA), and / or its sulfate ester, DHEA sulfate (DHEA-S). Nerve growth factor can increase the number of neurons that regenerate their axons, which can improve motor and sensory recovery and innervation of target muscles.

[0045] Steroids such as testosterone and / or estrogen may be used in the fascicular nerve graft 114. The fascicular nerve graft (e.g., fascicular nerve graft 114) may additionally or alternatively include cells, a mix of cells including multiple cell types in a mixed cell population, and / or cellular components. Cell types of the cells and the mix of cells in a mixed cell population include, but are not limited to, Schwann cells, macrophages, adipocytes, exosomes from Schwann cells, and the mentioned cell types. The source of the cells may be human, or may be differentiated from stem cells, or may be transdifferentiated from induced pluripotent stem cells. The added cells may be a source of cytokines and other factors that may improve nerve regeneration.

[0046] As described above, the fascicled nerve graft (e.g., fascicled nerve graft 114) can be disposed of, stored, and / or prepared in and / or with a buffer solution. For storage, the fascicled nerve graft can be placed in a storage container, which is then maintained at a temperature ranging from about −80° C. to room temperature (about 20° C. to about 22° C.). The storage container can be adaptable for flash freezing and maintenance at −80° C. or below for weeks, months, or years. The storage container can also be substantially airtight and backfilled with an inert gas. In some instances, the tissue is treated as disclosed herein (e.g., with enzymes or digestion solutions, and one or more wash solutions including serine-containing serum, which may include a buffer solution, and optionally, an additional wash solution including a buffer solution), and then transferred to a buffer solution, e.g., a buffered saline solution having a pH within the range of about 7.2 to about 7.6, e.g., a pH of about 7.3 to about 7.5, such as a pH of about 7.4, for storage prior to use in a medical procedure. Exemplary buffer solutions suitable for storage of grafts prepared according to the methods herein include, but are not limited to, PBS, saline catholyte, Tris-buffered saline, cacodylate buffer, Sorenson's phosphate buffer, phosphate-citrate buffer, and barbital buffer.

[0047] (Example) The present disclosure can be further understood by the following non-limiting examples. The examples are intended to illustrate embodiments of the above disclosure and should not be construed as narrowing its scope. Those skilled in the art will readily recognize that the examples suggest many other ways in which embodiments of the present disclosure may be implemented. It should be understood that numerous variations and modifications may be made while remaining within the scope of the present disclosure.

[0048] Example 1 Prior to preparation of the fasciculated nerve graft, nerve tissue was treated to remove native ECM material and epineurial sheath as follows. The following steps were performed under sterile conditions in a laminar flow hood. First, 100 μl of collagen type IV-specific digestive enzyme (e.g., 0.8 mg / mL collagenase IV) solution was transferred to a 1.5 ml centrifuge tube. A nerve tissue segment (approximately 3 mm long) and 100 μl (pipette setting) of the corresponding enzyme solution were placed in the 1.5 ml centrifuge tube for incubation at 37 °C for 2 to 4 hours. Taking great care not to physically damage the segment, the digestive enzyme solution was aspirated using a bulb-type transfer pipette. The segment was then washed three times with 1 ml of PBS, with gentle mixing by inversion between washes. The wash solution was removed with a transfer pipette as described above. As much fluid as possible was removed between each wash while ensuring the segment was not damaged. Contact between the test segment and the bulb-type transfer pipette tip was avoided.

[0049] The aspirated PBS was then replaced with, for example, 500 μl of fetal bovine serum (FBS), followed by incubation at 37°C for 45–55 minutes. The medium was then aspirated from the 1.5 ml centrifuge tube, ensuring that the segments were not damaged. These steps—replacing the aspirated medium with FBS, incubating at 37°C for 45–55 minutes, and removing from the incubator and aspirating the medium—were repeated twice. The medium was then aspirated from the 1.5 ml centrifuge tube and replaced with 1 ml of PBS. Using a dissecting microscope, a pair of precision surgical tweezers (e.g., No. 5 jeweler's tweezers) was used to visually separate the isolated bundles from the rest of the digested tissue for each segment. A pair of microscissors was used to carefully dissect the bundles from the digested tissue.

[0050] Example 2 Nerve tissue obtained from animal or human sources was prepared according to the procedure in Example 1, e.g., using collagenase type IV enzyme to digest the native ECM material and epineurial sheath of the nerve tissue. Nerve tissue not subjected to such processing was used as a control. The control nerve tissue and the processed nerve tissue were each embedded in paraffin. Cross-sections of the nerve samples with a thickness of 8 microns were obtained. The sections were then stained for laminin to identify nerve bundles. A histological bluing reagent was used to identify the presence of native ECM material. As shown in Figure 5, the control nerve tissue contained native ECM material around the nerve bundles, whereas the processed nerve tissue had little or no native ECM material around the nerve bundles, as shown in Figure 6.

[0051] Although the present disclosure has been made with reference to preferred embodiments, illustrative embodiments, and optional features, it should be understood that modifications and variations of the concepts disclosed herein may be employed by those skilled in the art, and that such modifications and variations are deemed to be within the scope of the present disclosure as defined by the appended claims. The specific embodiments and examples provided herein are examples of useful embodiments of the present disclosure and are not limiting, but merely illustrative. It will be apparent to those skilled in the art that the present disclosure may be practiced using many variations of the devices, device components, methods, and steps described herein. As will be recognized by those skilled in the art, methods and devices useful for the present methods can include many different optional configurations and processing elements and steps.

Claims

1. A fasciculated nerve graft comprising one or more nerve bundles, the fasciculated nerve graft being substantially free of epineurial sheaths and native extracellular matrix material.

2. The fasciculated nerve graft of claim 1 comprising a single nerve bundle.

3. 10. The fasciculated nerve graft of claim 1, comprising two or more nerve bundles.

4. 4. The fascicular nerve graft of claim 3, comprising between 2 and 20 nerve bundles.

5. 5. The fasciculated nerve graft of claim 3 or 4, comprising nerve bundles that are substantially similar in diameter to one another.

6. 6. The fasciculated nerve graft of claim 5, wherein the diameter of each of said nerve bundles is between about 50 μm and about 1 mm.

7. The bundled nerve graft of any one of claims 1 to 6, having a diameter of between about 50 μm and about 1 mm.

8. The bundled nerve graft of any one of claims 3 to 7, comprising nerve bundles that are substantially similar in length to one another.

9. The bundled nerve graft of any one of claims 1 to 8, having a length between about 3 mm and about 200 mm.

10. The bundled nerve graft according to any one of claims 1 to 9, wherein the one or more nerve bundles are entubated with an entubation material comprising a biocompatible material.

11. 11. The bundled nerve graft of any one of claims 1 to 10, wherein the one or more nerve bundles are embedded in or coated with a coating material comprising a biocompatible material.

12. 12. The bundled nerve graft of claim 10 or 11, wherein the biocompatible material of one or both of the entubation material or the coating material is biodegradable.

13. 13. The bundled nerve graft of any one of claims 10 to 12, wherein the biocompatible material of one or both of the entubation material and the coating material is an extracellular matrix material comprising one or more of collagen, chitosan, alginate, biodegradable polymers, cellulose, fibrinogen, fibrin, protein-based polymers, gelatin, polysaccharides, hydrogels, or non-native extracellular matrix materials.

14. 11. The fascicled nerve graft of claim 10, wherein a gel, collagen, gelatin, polysaccharide, hydrogel, fibrin, fibrinogen, alginate, or non-native extracellular matrix material is also surrounded by the entubation material.

15. 11. The bundled nerve graft of claim 10, wherein the entubation material comprises a seam, the seam being sealed with a biocompatible adhesive or sealant.

16. 16. The fasciculated nerve graft of any one of claims 1 to 15, wherein the one or more nerve bundles are from a human, a non-human animal, or both.

17. 17. The fascicular nerve graft of any one of claims 1 to 16, further comprising one or more of growth factors, cells, a mix of cells comprising multiple cell types in a mixed cell population, a cellular component, a nonsteroidal anti-inflammatory agent, or an immunosuppressant.

18. The fascicular nerve graft of any one of claims 1 to 17, which is a peripheral nerve graft or a spinal nerve graft.

19. 19. The bundled nerve graft of any one of claims 1-18, wherein at least about 50%, at least about 85%, at least about 95%, at least about 99%, or all of the native extracellular matrix material has been removed.

20. 20. The bundled nerve graft of any one of claims 1-19, wherein at least about 95%, at least about 99%, or all of the epineurial sheath has been removed.

21. 1. A method of preparing a fascicular nerve graft, comprising: providing at least one nerve tissue comprising one or more nerve bundles and comprising native extracellular matrix material and epineurial sheath; treating the at least one neural tissue with an enzyme that degrades the native extracellular matrix material and the epineurial sheath; washing the treated at least one nerve tissue to substantially remove and / or inactivate the enzymes and to substantially remove the native extracellular matrix material degradation products and the epineurial sheath degradation products, thereby producing the one or more nerve bundles substantially free of the native extracellular matrix material and the epineurial sheath; forming a fascicular nerve graft from at least one nerve bundle of said one or more nerve bundles substantially free of said native extracellular matrix material and said epineurial sheath; A method comprising:

22. 22. The method of claim 21, further comprising separating the one or more nerve bundles substantially free of the native extracellular matrix material and the epineurial sheath from one another, wherein the fasciculated nerve graft is formed from the separated one or more nerve bundles substantially free of the native extracellular matrix material and the epineurial sheath.

23. 23. The method of claim 22, wherein forming the bundled nerve graft comprises entubating the at least one nerve bundle of the isolated one or more nerve bundles with an entubation material.

24. 24. The method of any one of claims 21 to 23, wherein forming the bundled nerve graft comprises embedding or coating the at least one nerve bundle in a coating material comprising a gel, an adhesive, or both a gel and an adhesive.

25. 24. The method of claim 23, wherein forming the fascicular nerve graft comprises at least partially filling a space between the entubation material and the at least one nerve bundle, or the space between two or more nerve bundles in cases where two or more nerve bundles are used to form the fascicular nerve graft, or both, with a biocompatible material comprising one or more of a gel, collagen, gelatin, polysaccharide, hydrogel, fibrin, fibrinogen, alginate, cellulose, chitosan, or extracellular matrix material.

26. 24. The method of claim 23, wherein forming the bundled nerve graft comprises placing a coating material on a sheet of entubation material and entubating the at least one nerve bundle with the coated entubation material.

27. 23. The method of claim 22, wherein the at least one nerve bundle is embedded in or coated with a coating material comprising a gel, an adhesive, or a gel and an adhesive, and then the at least one embedded or coated nerve bundle is entubed in an entubation material comprising one or more of an extracellular matrix material, including one or more of collagen, chitosan, alginate, biodegradable polymers, cellulose, fibrinogen, fibrin, protein-based polymers, gelatin, polysaccharides, and / or hydrogels.

28. The method of any one of claims 23 to 27, wherein the biocompatible material of one or both of the entubation material and the coating material is biodegradable.

29. 29. The method of any one of claims 21 to 28, wherein the bundled nerve graft comprises a single nerve bundle.

30. 29. The method of any one of claims 21 to 28, wherein the bundled nerve graft comprises two or more nerve bundles.

31. 31. The method of claim 30, wherein the fascicular nerve graft comprises between 2 nerve bundles and 20 nerve bundles.

32. 32. The method of claim 30 or 31, wherein the fascicular nerve graft comprises nerve bundles that are substantially similar in diameter to one another.

33. 33. The method of claim 32, wherein the diameter of each of the nerve bundles is between about 50 μm and about 1 mm.

34. 34. The method of any one of claims 21 to 33, wherein the fascicular nerve graft has a diameter of between about 50 μm and about 1 mm.

35. 32. The method of claim 30 or 31, wherein the fascicular nerve graft comprises nerve bundles that are substantially similar in length to one another.

36. 36. The method of any one of claims 21 to 35, wherein the bundled nerve graft has a length between about 3 mm and about 200 mm.

37. 32. The method of claim 30 or 31, wherein forming the bundled nerve graft comprises modifying the lengths of the two or more nerve bundles substantially free of the native extracellular matrix material and the epineurial sheath to have substantially the same length.

38. 38. The method of any one of claims 21 to 37, wherein the at least one nervous tissue is from a human animal, a non-human animal, or both.

39. 39. The method of any one of claims 21-38, further comprising introducing one or more of the following into the fascicular nerve graft: growth factors, cells, a mix of cells comprising multiple cell types in a mixed cell population, a cellular component, a nonsteroidal anti-inflammatory drug, or an immunosuppressant.

40. 40. The method of any one of claims 21 to 39, wherein the fascicular nerve graft is a peripheral nerve graft or a spinal nerve graft.

41. 41. The method of any one of claims 21 to 40, wherein the at least one nerve tissue comprises two or more nerve tissues, and the bundled nerve graft is formed from a nerve bundle from the two or more nerve tissues.

42. 42. The method of any one of claims 21 to 41, wherein the enzyme is one or more of human collagenase, non-human specific collagenase, or non-specific collagenase, optionally the enzyme is collagenase type I, collagenase type III, collagenase type IV, or matrix metallopeptidase.

43. 43. The method of any one of claims 21 to 42, wherein the step of treating the nervous tissue with the enzyme is carried out at a temperature between about 4°C and about 37°C.

44. 43. The method of any one of claims 21 to 42, wherein the step of treating the nervous tissue with the enzyme is carried out for a period of between about 2 hours and about 24 hours.

45. 43. The method of any one of claims 21 to 42, wherein the step of treating the nervous tissue with the enzyme is carried out at a temperature of about 37°C for a period of about 2 hours to about 4 hours.

46. 43. The method of any one of claims 21 to 42, wherein the step of treating the nervous tissue with the enzyme is carried out at a temperature of about 4°C for a period of about 4 hours to about 24 hours.

47. 47. The method of any one of claims 21 to 46, wherein the step of treating the nervous tissue with the enzyme is carried out with agitation.

48. 48. The method of any one of claims 21 to 47, wherein the step of washing the processed nervous tissue is performed with agitation.

49. 49. The method of any one of claims 21 to 48, wherein the step of washing the processed nervous tissue is carried out at a temperature between about 4°C and about 40°C.

50. 50. The method of any one of claims 21 to 49, wherein the step of washing the processed neural tissue is carried out for a period ranging from about 1 minute to about 6 hours.

51. 51. The method of any one of claims 21 to 50, wherein the step of washing the processed nervous tissue is performed more than once.

52. suspending the washed neural tissue in a solution; incubating the suspended neural tissue in the solution; 52. The method of claim 51 further comprising:

53. 53. The method of claim 52, wherein the step of suspending the washed neural tissue in the solution, the step of incubating the suspended neural tissue in the solution, or both, is performed with agitation.

54. 54. The method of claim 52 or 53, wherein the suspended neural tissue is incubated at a temperature between about 4°C and about 37°C.

55. 55. The method of any one of claims 52 to 54, wherein the suspended neural tissue is incubated for a period of about 45 minutes to about 24 hours.

56. 56. The method of any one of claims 52 to 55, wherein the suspended neural tissue is incubated at a temperature of about 4°C for a period of about 6 hours to about 24 hours.

57. 57. The method of any one of claims 52 to 56, wherein the suspended neural tissue is incubated at a temperature of about 37°C for a period of about 45 minutes to about 60 minutes.

58. 58. The method of any one of claims 53 to 57, wherein the solution comprises a serine component comprising at least alpha-antitrypsin and alpha-2-macroglobulin.

59. 58. The method of any one of claims 52 to 57, wherein the solution is selected from the group consisting of fetal bovine serum, fetal goat serum, fetal horse serum, and fetal rabbit serum.

60. 60. The method of any one of claims 52 to 59, further comprising the steps of removing the solution after incubation and washing the neural tissue with a buffered solution.

61. 61. The method of claim 60, wherein the buffered solution has a pH of about 7.

4.

62. 62. The method of claim 60 or 61, wherein the neural tissue is washed with the buffered solution at a temperature of about 37°C for a period of at least 45 minutes.

63. 62. The method of claim 60 or 61, wherein the neural tissue is washed with the buffered solution at a temperature of about 4°C for a period of at least 1 hour.

64. 64. The method of any one of claims 60 to 63, wherein the step of washing the neural tissue with the buffered solution is performed with agitation.

65. 65. The method of any one of claims 21-64, wherein at least about 50%, at least about 85%, at least about 95%, at least about 99%, or all of the native extracellular matrix material has been removed.

66. 66. The method of any one of claims 21 to 65, wherein at least about 95%, at least about 99%, or all of the epineurial sheath is removed.

67. A method of treatment comprising implanting a nerve graft according to any one of claims 1 to 20 in a patient.

68. 67. A method of treatment comprising implanting in a patient the nerve graft produced by the method of any one of claims 21 to 66.

69. 69. The method of claim 67 or 68, wherein the patient is a human or non-human animal.

70. 70. The method of any one of claims 67-69, further comprising treating the patient with analgesic therapy, a nonsteroidal anti-inflammatory drug, a growth factor, or an immunosuppressant.